Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
AUTOR(ES)
Chan, Iris T.
FONTE
American Society for Clinical Investigation
RESUMO
Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic K-ras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor–independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=338267Documentos Relacionados
- Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
- While K-ras Is Essential for Mouse Development, Expression of the K-ras 4A Splice Variant Is Dispensable
- Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
- A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.
- Clinical significance of K-ras oncogene activation in ampullary neoplasms.